Results 41 to 50 of about 76,746 (287)

Current HDAC Inhibitors in Clinical Trials

CHIMIA, 2022
Epigenetic modifications in eukaryotic biological pathways can lead to the up- or downregulation of regulatory proteins contributing to disease onset and progression. In the last three decades, histone deacetylases (HDACs) are among the most studied epigenetic targets.
Elisabetta Di Bello, Beatrice Noce, Rossella Fioravanti, Antonello Mai   +3 more
openaire   +4 more sources

Histone deacetylase activity mediates acquired resistance towards structurally diverse HSP90 inhibitors [PDF]

, 2017
Heat shock protein 90 (HSP90) regulates multiple signalling pathways critical for tumour growth. As such, HSP90 inhibitors have been shown to act as effective anticancer agents in preclinical studies but, for a number of reasons, the same effect has not ...
Baker, Brough, Butler, Cercek, Chambers, Chen, Dickson, Eccles, Gaspar, George, Greer, Guo, Heath, Holmes, Jhaveri, Johnson, Kim, Kovacs, Kramer, Liu, Maloney, McCollum, McCollum, Page, Peserico, Price, Rae, Ramalingam, Rao, Rocha Dias, Ronnen, Ross, Sato, Scroggins, Sellappan, Sharp, Skehan, Smith, Solit, Tatokoro, Trepel, Wang, Wang, Wardley, Wei, Whitesell, Whitesell, Xu, Yang, Yong, Younes, Zhang, Zhang, Zupkovitz   +53 more
core   +1 more source

Comparative gene expression profiling of P. falciparum malaria parasites exposed to three different histone deacetylase inhibitors.

PLoS ONE, 2012
Histone deacetylase (HDAC) inhibitors are being intensively pursued as potential new drugs for a range of diseases, including malaria. HDAC inhibitors are also important tools for the study of epigenetic mechanisms, transcriptional control, and other ...
Katherine T Andrews, Archna P Gupta, Thanh N Tran, David P Fairlie, Geoffrey N Gobert, Zbynek Bozdech   +5 more
doaj   +1 more source

Introducing HDAC-Targeting Radiopharmaceuticals for Glioblastoma Imaging and Therapy

Pharmaceuticals, 2023
Despite recent advances in multimodality therapy for glioblastoma (GB) incorporating surgery, radiotherapy, chemotherapy and targeted therapy, the overall prognosis remains poor.
Liesbeth Everix, Elsie Neo Seane, Thomas Ebenhan, Ingeborg Goethals, Julie Bolcaen   +4 more
doaj   +1 more source

HDACs and HDAC Inhibitors in Cancer Development and Therapy [PDF]

Cold Spring Harbor Perspectives in Medicine, 2016
Over the last several decades, it has become clear that epigenetic abnormalities may be one of the hallmarks of cancer. Posttranslational modifications of histones, for example, may play a crucial role in cancer development and progression by modulating gene transcription, chromatin remodeling, and nuclear architecture.
Yixuan, Li, Edward, Seto
openaire   +2 more sources

HDACs and HDAC inhibitors in colon cancer [PDF]

Epigenetics, 2008
The histone deacetylase (HDAC) family of transcriptional co-repressors have emerged as important regulators of colon cell maturation and transformation. Pharmacological inhibitors of class I and II HDAC activity (HDACi) are potent inducers of growth arrest, differentiation and apoptosis of colon cancer cells in vitro and in vivo, implicating a role for
openaire   +2 more sources

HDAC1 inhibition by MS-275 in mesothelial cells limits cellular invasion and promotes MMT reversal [PDF]

, 2018
Peritoneal fibrosis is a pathological alteration of the peritoneal membrane occurring in a variety of conditions including peritoneal dialysis (PD), post-surgery adhesions and peritoneal metastases.
Battistelli, Cecilia, Bordoni, Veronica, DE TURRIS, Valeria, Domenici, Alessandro, Mai, Antonello, Manzione, Andrea, Mene', Paolo, Moioli, Alessandra, Noce, Valeria, Palladino, Marco, Rossi, Lucia, Strippoli, Raffaele, Tripodi, Marco, Valente, Sergio, Zwergel, Clemens   +14 more
core   +1 more source

Improved Histone Deacetylase Inhibitors as Therapeutics for the Neurodegenerative Disease Friedreich’s Ataxia: A New Synthetic Route

Pharmaceuticals, 2011
Friedreich’s ataxia (FRDA) is caused by transcriptional repression of the nuclear FXN gene encoding the essential mitochondrial protein frataxin. Based on the hypothesis that the acetylation state of the histone proteins is responsible for gene silencing
Joel M. Gottesfeld, James R. Rusche, Elisabetta Soragni, Vincent Jacques, Chunping Xu   +4 more
doaj   +1 more source

HDAC Inhibitors in Acute Myeloid Leukemia [PDF]

Cancers, 2019
Acute myeloid leukemia (AML) is a hematological malignancy characterized by uncontrolled proliferation, differentiation arrest, and accumulation of immature myeloid progenitors. Although clinical advances in AML have been made, especially in young patients, long-term disease-free survival remains poor, making this disease an unmet therapeutic challenge.
Edurne San José-Enériz, Naroa Gimenez-Camino, Xabier Agirre, Felipe Prosper   +3 more
openaire   +3 more sources

Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity [PDF]

, 2016
Background: Histone deacetylase inhibitors (HDACi) exert multiple cytotoxic actions on cancer cells. Currently, different synthetic HDACi are in clinical use or clinical trials; nevertheless, since both pro-invasive and anti-invasive activities have been
Andrade, Ricardo, Arluzea, Jon, Aréchaga, Juan, De Wever, Olivier, Díaz-Núñez, María, Díez-Torre, Alejandro, Silió, Margarita   +6 more
core   +4 more sources